Combined Plasma Biomarkers for Diagnosing Mild Cognition Impairment and Alzheimer's Disease
Combined Plasma Biomarkers for Diagnosing Mild Cognition Impairment and Alzheimer's Disease
复制标题
DOI：
10.1021/cn400129p
复制
发表时间：
2013-12-01
影响因子：
5
通讯作者：
Yang, Hong-Chang
中科院分区：
文献类型：
--
作者：
Chiu, Ming-Jang;Yang, Shieh-Yueh;Yang, Hong-Chang
一种高度敏感的免疫测定法，免疫磁还原法，用于测量与阿尔茨海默病（AD）相关的几种血浆生物标志物。这些生物标志物包括A -40、A -42和tau蛋白。样本由四组组成：健康对照组（n = 66），轻度认知障碍（MCI, n = 22），非常轻度痴呆（n = 23）和轻度痴呆，均由AD引起（n = 22）。结果发现，健康对照组的A -42和tau蛋白浓度明显低于其他各组。血浆A β -42和tau蛋白对MCI与AD鉴别的敏感性和特异性均在0.9左右（0.88-0.97）。然而，血浆A β -42和tau蛋白浓度都不是区分MCI和AD的充分参数。我们提出了一个参数，即血浆A β -42和tau蛋白水平的产物，以区分MCI和AD。灵敏度为0.80，特异度为0.82。综上所述，联合血浆生物标志物的使用不仅可以区分健康对照组和AD患者的前驱期和痴呆期，还可以区分前驱期AD与痴呆期AD。
A highly sensitive immunoassay, the immunomagnetic reduction, is used to measure several biomarkers for plasma that is related to Alzheimer's disease (AD). These biomarkers include A beta-40, A beta-42, and tau proteins. The samples are composed of four groups: healthy controls (n = 66), mild cognitive impairment (MCI, n = 22), very mild dementia (n = 23), and mild-to-serve dementia, all due to AD (n = 22). It is found that the concentrations of both A beta-42 and tau protein for the healthy controls are significantly lower than those of all of the other groups. The sensitivity and the specificity of plasma A beta-42 and tau protein in differentiating MCI from AD are all around 0.9 (0.88-0.97). However, neither plasma A beta-42 nor tau-protein concentration is an adequate parameter to distinguish MCI from AD. A parameter is proposed, which is the product of plasma A beta-42 and tau-protein levels, to differentiate MCI from AD. The sensitivity and specificity are found to be 0.80 and 0.82, respectively. It is concluded that the use of combined plasma biomarkers not only allows the differentiation of the healthy controls and patients with AD in both the prodromal phase and the dementia phase, but it also allows AD in the prodromal phase to be distinguished from that in the dementia phase.